<DOC>
	<DOCNO>NCT02620007</DOCNO>
	<brief_summary>The primary objective trial ass whether 12-week treatment Ciprofloxacin Rifaximin superior placebo obtain endoscopic remission adherent-invasive E. coli ( AIEC ) -colonized patient ileal Crohn disease ( CD ) , without involvement caecum right colon .</brief_summary>
	<brief_title>Evaluation Adherent Invasive E. Coli Eradication Adult Crohn Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>CD ileum , without involvement caecum right colon Colonoscopy show active lesion define CDEISm score &gt; 6 Informed consent participate study Prescription steroid treatment : Budesonide , Prednisone ( Prednisolone ) independently entry study Patients respond budesonide ( initial dose 9 mg/d ) prednisone prednisolone ( initial dose 40 mg/d ) , define 70 point decrease CDAI preinclusion inclusion visit , Patients colonize AIEC initial ileal biopsy . Ileal stenosis cross endoscope , Infliximab treatment receive less 8 week inclusion study , Adalimumab treatment receive less 4 week inclusion study , Vedolizumab treatment receive less 8 week inclusion study , Hypersensitivity Ciprofloxacin , quinolones , excipients ( cellulose microcrystalline , crospovidone , maize starch , magnesium stearate , silica colloidal anhydrous , , hypromellose titanium dioxide E171 , macrogol 4000 , ) , Tizanidine , Probenecid , Theophylline , Xanthine derivatives , Phenytoin , oral anticoagulant , Ropinirole treatment , Hypersensitivity Rifaximin , excipients ( sodium starch glycolate type A , glycerol distearate , colloidal anhydrous silica , talc , microcrystalline cellulose , hypromellose , titanium dioxide , disodium edentate , propylene glycol , red iron oxide E172 ) , Previous extensive ileal surgery ( â‰¥ 1 meter measure pathology and/or surgical report ) , Short bowel syndrome , Need intestinal resection fistula , abscess intestinal obstruction , Renal failure ( creatinine clearance &lt; 30 mL/min/1.73m2 ) , Liver failure ( V factor &lt; 50 % ) , Past history epilepsy , No health insurance , Pregnant lactate woman , Refusal double effective contraception , Patients already include biomedical research observational study ( e.g : registry , cohort ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adult</keyword>
	<keyword>AIEC</keyword>
</DOC>